SCHEMBL29978733

SCHEMBL29978733

NS(=O)(=O)NCCNc1nonc1C(=NO)Nc1cccc(C(F)(F)F)c1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 12/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2C9 P11712 1/20 0.49
TDO2 P48775 1/20 0.49
IDO2 Q6ZQW0 1/20 0.49
ALDH1A1 P00352 1/20 0.43
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
CA9 Q16790 2/20 0.41
CA12 O43570 1/20 0.41
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
LMNA P02545 1/20 0.39
TP53 P04637 1/20 0.39
MAPT P10636 1/20 0.39
ALOX15 P16050 1/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39
CA4 P22748 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL147127 1.00 IDO1 (0.49) IDO1CYP3A4CYP2C9TDO2IDO2
SCHEMBL147126 1.00 IDO1 (0.49) IDO1CYP3A4CYP2C9TDO2IDO2
SCHEMBL147503 0.95 IDO1 (0.44) IDO1CYP3A4CYP2C9TDO2IDO2
SCHEMBL147502 0.95 IDO1 (0.44) IDO1CYP3A4CYP2C9TDO2IDO2
SCHEMBL30448914 0.91 IDO1 (0.49) IDO1CYP3A4CYP2C9TDO2IDO2
SCHEMBL30449652 0.91 IDO1 (0.49) IDO1CYP3A4CYP2C9TDO2IDO2
SCHEMBL147069 0.91 IDO1 (0.49) IDO1CYP3A4CYP2C9TDO2IDO2
SCHEMBL147068 0.91 IDO1 (0.49) IDO1CYP3A4CYP2C9TDO2IDO2
SCHEMBL20198880 0.89 IDO1 (0.47) IDO1CYP3A4CYP2C9TDO2IDO2
SCHEMBL20198881 0.88 IDO1 (0.46) IDO1CYP3A4CYP2C9TDO2IDO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11896615-B2 Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators JUNO THERAPEUTICS, INC. (US) 2024-02-13 US claimed
EP-4190335-A1 IMMUNOTHERAPY METHODS AND COMPOSITIONS INVOLVING TRYPTOPHAN METABOLIC PATHWAY MODULATORS Juno Therapeutics, Inc. (US) 2023-06-07 EP claimed
EP-3525803-B1 IMMUNOTHERAPY METHODS AND COMPOSITIONS INVOLVING TRYPTOPHAN METABOLIC PATHWAY MODULATORS JUNO THERAPEUTICS INC (US) 2022-12-07 EP claimed
US-11896615-B2 Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators JUNO THERAPEUTICS, INC. (US) 2024-02-13 US disclosed
EP-4190335-A1 IMMUNOTHERAPY METHODS AND COMPOSITIONS INVOLVING TRYPTOPHAN METABOLIC PATHWAY MODULATORS Juno Therapeutics, Inc. (US) 2023-06-07 EP disclosed
EP-3525803-B1 IMMUNOTHERAPY METHODS AND COMPOSITIONS INVOLVING TRYPTOPHAN METABOLIC PATHWAY MODULATORS JUNO THERAPEUTICS INC (US) 2022-12-07 EP disclosed
US-20220323558-A1 CANCER VACCINES PFIZER INC. (US) 2022-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11896615-B2 Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators KYNU, IDO1, IDO2 IDO1 2/4885CYP3A4 1445/4885CYP2C9 991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.